Table 1.
Model | Strategy, Nuclease | Delivery, Vector/s | Cardiac Findings | Reference | |||
---|---|---|---|---|---|---|---|
RT-PCR | WB | ICC | Function, etc. | ||||
Δex46–51, Δex46–47, ex50dup. from patient fibroblasts | DMD Δex45–55, SpCas9 | Nucleofection, dual plasmid | Skipping observed | DYS observed | DYS+ cells observed | iCMs from treated iPSCs (Δex46–51, Δex46–47) had reduced CK release in hypo-osmotic conditions | 2016 Young et al. [92] |
Δex48–50 from patient fibroblasts | DMD ex51 NHEJ repair or skipping, LbCpf1/AsCpf1 | Nucleofection, single plasmid | Reframing, skipping observed | DYS observed in all strategies | DYS+ cells observed in all strategies | iCMs from reframed iPSCs had significantly more mitochondria and increased respiratory capacity | 2017 Zhang et al. [94] |
Δex8–9, CRISPR-generated from healthy PBMCs in study; Δex3–7 from patient (source not stated) | DMD Δex3-9, Δex6-9, Δex7–11, SpCas9 | Nucleofection, dual plasmid | Skipping observed in all strategies | DYS observed in all strategies (Δex7–11 had least DYS) | DYS+ cells observed in all strategies | Ca2+ dynamics improved after treatment, but only significant in Δex3–9 iCMs; EHM from treated iCMs had enhanced contractility, with Δex3–9 showing best results | 2017 Kyrychenko et al. [95] |
Δex48–50, pseudo-ex47, ex55–59dup. from patient PBMCs | DMD ex51 skipping, cryptic splice site removal in ex47, Δ55–59dup., respectively, SpCas9 | Nucleofection, single plasmid | Skipping observed in all strategies | DYS observed in all strategies | DYS+ cells observed in all strategies | EHMs from corrected iCMs had significantly improved contractile force; 30% or 50% DYS+ CMs sufficient for partial or complete recovery, respectively | 2018 Long et al. [96] |
Δex51 from patient PBMCs | DMD ex50 skipping, dSaCas9-TAM | Lipotransfection, single plasmid (with separate Ugi plasmid) | Skipping observed | DYS observed | DYS+ cells observed | iCMs from treated iPSCs had significantly reduced CK release in hypo-osmotic conditions | 2018 Yuan et al. [97] |
Δex48–50 from patient fibroblasts | DMD ex51 NHEJ repair or skipping, SpCas9 | Nucleofection, single plasmid | - | 67%–100% DYS of WT observed | DYS+ cells observed | - | 2018 Amoasii et al. [98] |
Δex44 from patient PBMCs | DMD ex43, 45 NHEJ repair or skipping, SpCas9 | Nucleofection, single plasmid | - | DYS observed | DYS+ cells observed | - | 2019 Min et al. [99] |
Abbreviations: RT-PCR, reverse transcription-polymerase chain reaction; WB, Western blot; ICC, immunocytochemistry; DYS, dystrophin; CK, creatine kinase; NHEJ, non-homologous end-joining; PBMCs, peripheral blood mononuclear cells; EHM, engineered heart muscle.